Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.50 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17583879 | 0.89 | ESR2 (0.51) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL22334381 | 0.88 | DDB1 (0.52) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL31297088 | 0.86 | UCHL1 (0.48) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL30150268 | 0.83 | ESR2 (0.59) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL11997414 | 0.83 | ESR2 (0.55) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL1958196 | 0.83 | ESR2 (0.59) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL25259759 | 0.83 | ADORA1 (0.46) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL31057166 | 0.83 | ADORA1 (0.46) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL25300998 | 0.83 | ADORA1 (0.46) | ESR2MAPK1NR1H2UCHL1ABHD6 | |
| SCHEMBL25302754 | 0.82 | UCHL1 (0.46) | ESR2MAPK1NR1H2UCHL1ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253993-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2020-08-13 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | ESR2 3851/4885MAPK1 83/4885NR1H2 1875/4885 |
| US-20200253993-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | C1R, RDX, F12 | ESR2 1495/4885MAPK1 3667/4885NR1H2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.